Aptose Biosciences Inc. (NASDAQ:APTO) Forecasted to Earn FY2023 Earnings of $0.22 Per Share

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) – Equities research analysts at Oppenheimer dropped their FY2023 earnings per share estimates for Aptose Biosciences in a research note issued on Wednesday, March 27th, according to Zacks Investment Research. Oppenheimer analyst M. Biegler now forecasts that the biotechnology company will post earnings of $0.22 per share for the year, down from their prior forecast of $0.23. Oppenheimer currently has a “Outperform” rating and a $6.00 price objective on the stock.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01).

A number of other research firms have also recently commented on APTO. Zacks Investment Research cut shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. HC Wainwright set a $9.00 target price on shares of Aptose Biosciences and gave the stock a “buy” rating in a research note on Friday, March 22nd. Citigroup started coverage on shares of Aptose Biosciences in a research note on Friday, January 25th. They set an “outperform” rating and a $6.00 target price on the stock. Finally, Royal Bank of Canada started coverage on shares of Aptose Biosciences in a research report on Friday, March 1st. They set an “outperform” rating and a $6.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $5.71.

NASDAQ APTO traded down $0.02 on Friday, reaching $1.83. 103,226 shares of the stock were exchanged, compared to its average volume of 196,845. Aptose Biosciences has a one year low of $1.57 and a one year high of $4.55. The stock has a market cap of $73.66 million, a price-to-earnings ratio of -2.13 and a beta of 1.61.

In other Aptose Biosciences news, CFO Gregory K. Chow purchased 15,000 shares of Aptose Biosciences stock in a transaction that occurred on Wednesday, March 13th. The shares were bought at an average price of $1.75 per share, for a total transaction of $26,250.00. Following the completion of the transaction, the chief financial officer now owns 122,014 shares of the company’s stock, valued at approximately $213,524.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total transaction of $43,800.00. The disclosure for this sale can be found here. In the last quarter, insiders have bought 35,000 shares of company stock worth $63,750.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Noven Financial Group Inc. purchased a new stake in shares of Aptose Biosciences during the fourth quarter valued at $27,000. Geode Capital Management LLC bought a new stake in shares of Aptose Biosciences in the fourth quarter valued at about $33,000. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 5,890 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Aptose Biosciences in the third quarter valued at about $125,000. Finally, Virtu Financial LLC bought a new stake in shares of Aptose Biosciences in the first quarter valued at about $198,000. Institutional investors own 7.68% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Story: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.